Patents by Inventor Yan-Ling Zhang

Yan-Ling Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9790184
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Grant
    Filed: July 29, 2013
    Date of Patent: October 17, 2017
    Assignees: The Broad Institute, Inc., The General Hospital Corporation
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis, Tracey Lynn Petryshen
  • Publication number: 20170217955
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: May 5, 2016
    Publication date: August 3, 2017
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
  • Publication number: 20160347761
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
  • Patent number: 9447030
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: September 20, 2016
    Assignees: Massachusetts Institute of Technology, The General Hospital Corporation, The Broad Institute, Inc.
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • Publication number: 20160251351
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: May 5, 2016
    Publication date: September 1, 2016
    Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
  • Patent number: 9365498
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: June 14, 2016
    Assignees: The Broad Institute, Inc., The General Hospital Corporation, Massachusetts Institute of Technology
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • Publication number: 20150191427
    Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 9, 2015
    Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis
  • Publication number: 20140335550
    Abstract: The invention relates to a compound of Formula I: F1-X1-L1-X2-P1-X3-G1??(Formula I).
    Type: Application
    Filed: May 1, 2014
    Publication date: November 13, 2014
    Applicant: The Broad Institute, Inc.
    Inventors: Yan-Ling Zhang, Edward Holson, Florence F. Wagner
  • Publication number: 20140080800
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 20, 2014
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • Publication number: 20140080802
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R2a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 20, 2014
    Inventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen Haggarty, Yan-Ling Zhang
  • Publication number: 20120264403
    Abstract: A communication control system includes an electronic device and a communication apparatus paired with the electronic device. The electronic device includes an input unit, a first BLUETOOTH unit, and a dialing control module. The input unit generates commands in response to operations of a user. The dialing control module generates dial information when a dialing command is received, and controls the first BLUETOOTH unit to transmit the dial information to the communication apparatus. The communication apparatus includes a wireless communication unit, a second BLUETOOTH unit, and a dialing module. The dialing module controls the wireless communication unit to dial according to the dial information. The dialing module also controls the second BLUETOOTH unit to transmit real-time dial information and voice signals of the user to the electronic device. A related method is also provided.
    Type: Application
    Filed: July 26, 2011
    Publication date: October 18, 2012
    Applicants: HON HAI PRECISION INDUSTRY CO., LTD., HONG FU JIN PRECISION INDUSTRY (SHENZHEN) CO., LTD.
    Inventors: KUAN-HONG HSIEH, MING-TSUNG CHEN, HUI-FANG PENG, YAN-LING ZHANG
  • Patent number: 8071348
    Abstract: The present invention provides protein tyrosine phosphatases (PTP) in which the invariant aspartate residue and the invariant glutamine residue are each replaced with a replacement amino acid residue, wherein the replacement residues together cause a reduction in catalytic rate (kcat) of the enzyme and an increase in substrate-binding affinity (Kd) of the enzyme. The present invention further provides methods for identifying a substrate of a PTP. Also provided are kits for identifying a substrate of a PTP. Additionally, the present invention provides methods for identifying an agent that alters interaction between a PTP and a substrate of the PTP. The invention also provides methods for reducing the activity of a substrate of a PTP.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: December 6, 2011
    Assignee: Albert Einstein College of Medicine of Yeshiva University
    Inventors: Zhong-Yin Zhang, Laiping Xie, Yan-Ling Zhang
  • Patent number: 7521473
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Grant
    Filed: February 23, 2005
    Date of Patent: April 21, 2009
    Assignee: Wyeth
    Inventors: Jinbo Lee, Zhao-Kui Wan, Douglas P. Wilson, Bruce C. Follows, Steven J. Kirincich, Michael J. Smith, Jun-Jun Wu, Kenneth W. Foreman, David V. Erbe, Yan-Ling Zhang, Weixin Xu, Steve Y. Tam
  • Publication number: 20090048286
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: September 23, 2008
    Publication date: February 19, 2009
    Applicant: Wyeth
    Inventors: Jinbo Lee, Steven J. Kirincich, Michael J. Smith, Douglas P. Wilson, Bruce C. Follows, Zhao-Kui Wan, Diane M. Joseph-McCarthy, David V. Erbe, Yan-Ling Zhang, Weixin Xu, Steve Y. Tam
  • Publication number: 20050203087
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: February 23, 2005
    Publication date: September 15, 2005
    Inventors: Jinbo Lee, Zhao-Kui Wan, Douglas Wilson, Bruce Follows, Steven Kirincich, Michael Smith, Jun-Jun Wu, Kenneth Foreman, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam
  • Publication number: 20050203081
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: February 23, 2005
    Publication date: September 15, 2005
    Inventors: Jinbo Lee, Steve Kirincich, Michael Smith, Douglas Wilson, Bruce Follows, Zhao-Kui Wan, Diane Joseph-McCarthy, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam
  • Publication number: 20030170855
    Abstract: The present invention provides protein tyrosine phosphatases (PTP) in which the invariant aspartate residue and the invariant glutamine residue are each replaced with a replacement amino acid residue, wherein the replacement residues together cause a reduction in catalytic rate (kcat) of the enzyme and an increase in substrate-binding affinity (Kd) of the enzyme. The present invention further provides methods for identifying a substrate of a PTP. Also provided are kits for identifying a substrate of a PTP. Additionally, the present invention provides methods for identifying an agent that alters interaction between a PTP and a substrate of the PTP. The invention also provides methods for reducing the activity of a substrate of a PTP.
    Type: Application
    Filed: January 10, 2003
    Publication date: September 11, 2003
    Inventors: Zhong-Yin Zhang, Laiping Xie, Yan-Ling Zhang
  • Patent number: 5338670
    Abstract: A fermentation level cultivation of Bordetella pertussis bacteria on commercial scale is described. The critical factors in large scale cultivation of the bacteria are the presence of an antifoam agent and maintaining proper oxygen level and iron content in the culture medium. Pertussis toxin produced by the bacteria parallels the rate of growth of the bacteria.
    Type: Grant
    Filed: December 11, 1992
    Date of Patent: August 16, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Ronald D. Sekura, Yan-Ling Zhang, Joseph Shiloach